Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Rituximab in Patients With B-Cell Lymphoproliferative Disorders Associated With Pharmacologic Immunosuppression

NCT00003716 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT00003716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Rituximab in Patients With B-Cell Lymphoproliferative Disorders Associated With Pharmacologic Immunosuppression
Lead sponsor
Stanford University
Phase
Phase 2
Overall status
Completed
Start date
March 31, 1998
Completion date
January 31, 2007
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma